Last week, Sun Pharmaceutical, an Indian group held by billionaire Dilip Shanghvi, announced it took over Ranbaxy in a deal valued at over $3 billion, changing the ranking of India’s biggest players, with the newly-created entity now leading the market.
“We see tremendous growth opportunities especially in ROW which includes Romania markets. We bring to the table a proven ability to turnaround distressed assets,” Frederick Castro, Sun Pharmaceutical’s spokesperson, told ZF.
With revenue of almost EUR120 million in 2013, Terapia is Romania’s largest drug maker and it is set to play a key role in the new Indian entity. The Cluj plant is Ranbaxy’s largest in Europe. On the other hand, Sun Pharma has a single facility in Europe, in Hungary, where it produces active ingredients and Terapia is one of the clients.
To sell in Europe, Indian companies need local facilities and this is why any new plant is extremely important.
Sun Pharma sells a single product in Romania, in the oncology field, while at the level of Ranbaxy, the Romanian plant represented the export platform for the entire region.
The deal between the two Indian companies comes at an extremely difficult time for Ranbaxy, which has recently had to exit the US market.
“The transaction allows Sun Pharma to build on Ranbaxy’s strong global footprint and well established product portfolio. The product offerings are complementary,” Sun Pharma’s spokesperson also told ZF.
Terapia exports to Russia, Ukraine, Western Europe and other states and the product boasting the highest sales abroad is Faringosept.
“The decision to acquire Ranbaxy was made post a detailed due diligence of Ranbaxy’s business; Terapia alone could not have influenced the decision,” Frederick Castro also said.
The combined 2013 businesses of Sun and Ranbaxy are valued at $4.3 billion, placing the newly forged group on the fifth position on the global generics market after Teva, Sandoz, Actavis and Mylan.
(English version by Catalina Apostoiu)